India: Patent

The June 2026 edition of Dentons Link Legal IP & Technology Newsletter examines the global intellectual property ecosystem's strong momentum, featuring record-high filings, AI-driven innovation surges, and pivotal rulings that reflect technological advancement and evolving regulatory priorities. From bizarre patent cases like motorized pasta forks to multimillion-dollar verdicts collapsed by procedural flaws, the newsletter explores landmark decisions in pharmaceutical patents, trademark enforcement, and AI

In Astral Ltd. v. M/s Astral Marketing Syndicate & Anr., CS (COMM) 294/2024, the Delhi High Court dismissed an application seeking rejection of the plaint for lack of territorial jurisdiction. The Court held that, at the stage of considering an objection under Order VII Rule 11 of the Code of Civil Procedure, the averments in the plaint must be accepted as true. It further observed that an interactive listing on a third-party platform such as Justdial, through which consumers can access product catalogues, initiate enquiries, and contact the Defendant, is sufficient to prima facie confer territorial jurisdiction in an internet-based trademark dispute.

While legal merits are important, experienced business leaders know that litigation is only one component of a broader commercial decision.

Every good business has some kind of story behind it, like real innovation. Sometimes it starts with a breakthrough invention, other times it’s more like a recognisable brand identity, proprietary software, or an iconic product layout.

India's new SHANTI Act, 2025 marks a significant shift in nuclear energy governance by conditionally allowing patents for inventions related to peaceful uses of nuclear energy and radiation. This legislative change opens opportunities for innovators in biotechnology and nuclear sectors while imposing specific disclosure requirements and restrictions on sensitive technologies.

Every growing business develops valuable assets beyond physical infrastructure and financial resources. Brand identity, product designs, software, inventions, customer databases and proprietary business processes...

Semaglutide, sold under the blockbuster brands Ozempic and Wegovy, has become one of the most talked-about drugs in recent memory. It belongs to a class of medicines known as GLP-1 receptor agonists, which mimic a hormone that regulates appetite and blood sugar.

Green tech and clean energy innovations are no longer “optional extras” for the Indian economy—they are central to India’s climate commitments, energy security, and long-term industrial growth.

Assume your doctor prescribes a drug to you. The brand-name version costs $300 a month. Another generic drug on the other hand will cost $30. As most people would, you would also purchase the cheaper one. That generic cheaper bottle exists as a result of a delicate legal balancing act, an act that the U.S. Supreme Court is now reconsidering in a case that could change pharmaceutical competition for decades.